Amylin drugs have become the next big thing in obesity. Eli Lilly CEO David Ricks, understandably, thinks his rivals don’t ...

LONDON & SAN FRANCISCO--(BUSINESS WIRE)--Verdiva Bio Limited (“Verdiva” or “the Company”) a clinical-stage biopharmaceutical company focused on developing innovative therapies for obesity and ...

The company's obesity drug candidate VK3019 showed stronger early weight-loss signals than Novo Nordisk’s amylin therapy. ・The company said enrollment has been completed across both Phase 3 Vanquish ...

Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today ...

No. 11 / 2026Zealand Pharma and Roche to advance petrelintide, an amylin analog, to Phase 3 trials for chronic weight ...

Roche and Zealand Pharma announced last month that their amylin analog petrelintide elicited a 9% placebo-controlled weight ...

Eli Lilly said it will start late-stage trials on its experimental amylin obesity drug next month after it showed encouraging results in a mid-stage study. The highest dose of the weekly injection, ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Allison DeAngelis is the ...

Eli Lilly CEO David Ricks has criticized AbbVie’s amylin-based obesity drug strategy, arguing Lilly’s selective receptor targeting offers better results with fewer side effects. AbbVie defended its ...

Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today poster presentations highlighting multiple programs at the ...

Please provide your email address to receive an email when new articles are posted on . Petrelintide is a once-weekly amylin analog currently under investigation for the treatment of obesity. The ...

SAN DIEGO (Reuters) - Analysis of an earlier trial found a "clinically insignificant" link between changes in heart rhythms and use of Bydureon, a long-acting diabetes drug being developed by Amylin ...